La Nua Day Hospital Mental Health Centre Trials

La Nua Day Hospital Mental Health Centre	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Allen, Rebecca H

uAspire, NCT06308653: Psilocybin for Major Depressive Disorder (MDD)

Recruiting

240

Psilocybin 25 mg, Psilocybine, Psilocibin, Indocybin, Inactive Placebo, Microcrystalline Cellulose (MCC), Placebo, Psilocybin 5 mg, Psilocybine, Psilocibin, Indocybin, Active Comparator, Psychosocial Support

Usona Institute, Worldwide Clinical Trials

Depressive Disorder, Major

04/26

12/26

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

IMPACT-2, NCT06215261: An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD

Recruiting

Europe, US, RoW

Methylone

Transcend Therapeutics

Post Traumatic Stress Disorder

12/25

NCT05458037: RCT of Pain Perception With Fast and Slow Tenaculum Application

Recruiting

N/A

150

Speed of tenaculum application

Women and Infants Hospital of Rhode Island

Pain, Acute, Pain, Procedural

12/26

MeRT-TBI-005, NCT02990793: Clinical Trial to Evaluate the Safety and Efficacy of MeRT Treatment in Post-Traumatic Stress Disorder

Recruiting

N/A

152

Active MeRT Treatment, rTMS Active Stimulator, Sham MeRT Treatment, rTMS Sham Stimulator

Wave Neuroscience, Texas A&M University, GilpinPhillips BIOMED, LLC, Peachtree BioResearch Solutions

PostTraumatic Stress Disorder, Traumatic Brain Injury, Postconcussive Symptoms

08/25

10/25

MiMP, NCT05363371: Minds and Mentors Program- R33

Recruiting

N/A

240

Minds and Mentors, Twelve Step Intervention Group

University of Alabama, Tuscaloosa, University of Alabama at Birmingham, Tuscaloosa Veterans Affairs Medical Center, Pathway Healthcare, LLC

Opioid Use Disorder, Substance Use Disorders, Medication Assisted Treatment

08/24

OLO, NCT05819021: Open Label Optimization Study

Recruiting

N/A

1000

SAINT® Neuromodulation System (NMS), TMS

Magnus Medical

Major Depressive Disorder

10/26

04/27

RECOVER, NCT03887715: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

Recruiting

N/A

6800

Vagus Nerve Stimulation (VNS), VNS

LivaNova

Treatment Resistant Depression

02/28

12/30

DiBuono, Mark

REGAiN-1B, NCT04873232: A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy

Completed

106

Engensis, Placebo

Helixmith Co., Ltd.

Diabetic Peripheral Neuropathy

09/23

07/24

NCT05397639 / 2021-003405-22: Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

Recruiting

375

Europe, US, RoW

Masupirdine 50 mg, SUVN-502, Masupirdine 100 mg, Placebo

Suven Life Sciences Limited, Suven Life Sciences Ltd

Agitation, Alzheimer's Type Dementia

12/25

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Terminated

1125

Canada, US, RoW

Simufilam, PTI-125, Placebo

Cassava Sciences, Inc., Premier Research Group plc

Alzheimer Disease

12/24

NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting

2996

Japan, US

Donanemab, LY3002813, Placebo

Eli Lilly and Company

Alzheimer Disease

11/27

NCT05439603: ANC-501 in the Treatment of Adults With Major Depressive Disorder

Completed

ANC-501

Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.

Major Depressive Disorder

08/23

10/23

NCT05081245: ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)

Recruiting

150

Canada, US, RoW

ML-004 (IR)/(ER) tablet, ML-004 Placebo

MapLight Therapeutics

Autism Spectrum Disorder

10/26

11/26

CYPRESS, NCT05895552: A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain

Terminated

209

RTA 901, BIIB143, Cemdomespib, RTA 901-Matching Placebo

Biogen

Diabetic Peripheral Neuropathic Pain

11/24

PROGRESS-AD, NCT06079190: Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

Active, not recruiting

367

Europe, Canada, US, RoW

GSK4527226, Placebo

GlaxoSmithKline, Alector Inc.

Alzheimer's Disease

11/26

NCT03788811: ERG Components in Schizophrenia and Bipolar Disorder Type I

Active, not recruiting

N/A

300

Canada, US, RoW

ERG assessment (RSPA)

diaMentis Inc.

Schizophrenia, Bipolar I Disorder

12/24

Robison, Reid

uAspire, NCT06308653: Psilocybin for Major Depressive Disorder (MDD)

Recruiting

240

Usona Institute, Worldwide Clinical Trials

Depressive Disorder, Major

04/26

12/26

NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

Active, not recruiting

255

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

06/25

04/26

EBS-101-TD-391, NCT06021522: A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

Recruiting

150

Europe, Canada, US, RoW

Ecopipam, Ecopipam Hydrochloride

Emalex Biosciences Inc.

Tourette Syndrome

12/26

03/27

D1AMOND, NCT05615220: Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults

Completed

216

Europe, Canada, US, RoW

Ecopipam Hydrochloride

Emalex Biosciences Inc.

Tourette Disorder

01/25

02/25

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

NCT05081245: ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)

Recruiting

150

Canada, US, RoW

ML-004 (IR)/(ER) tablet, ML-004 Placebo

MapLight Therapeutics

Autism Spectrum Disorder

10/26

11/26

BVR-100-102, NCT06037668: A Randomized, Controlled Study of Two At-Home Self-Guided Virtual Reality Interventions for Adults With Social Anxiety Disorder.

Completed

N/A

BVR-100, BES-100

Sumitomo Pharma America, Inc., BehaVR LLC

Social Anxiety Disorder (SAD)

12/23

01/24

Nery, Fabiano G

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

Duchemin, Anne-Marie

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

NCT06820723: A Mechanistic Study to Assess a Single Dose of CYB003 in Participants with Depression and Anxiety

Not yet recruiting

CYB003, Placebo

Ohio State University

Depression, Anxiety, Major Depressive Disorder

03/27

11/27

NCT05032105: The Impact of Focused Ultrasound Thalamotomy of the Anterior Nucleus for Focal-Onset Epilepsy on Anxiety

Recruiting

Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA)

Ohio State University

Anxiety, Medication-refractory Focal-onset Epilepsy

12/25

Recruiting

N/A

6800

Vagus Nerve Stimulation (VNS), VNS

LivaNova

Treatment Resistant Depression

02/28

12/30

House, Brindley

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

UNIKET, NCT05046184: Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets

Completed

165

Ketamine Hydrochloride, Midazolam injection

University of Texas Southwestern Medical Center

Major Depressive Disorder, Healthy Controls

04/25

Lindsay, Tenekia

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

Kwon, Sarah

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

ABT-CIP-10494, NCT06423430: Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

Recruiting

N/A

100

Sham-stimulation, Active-stimulation

Abbott Medical Devices

Treatment Resistant Depression

04/27

04/29

Recruiting

N/A

6800

Vagus Nerve Stimulation (VNS), VNS

LivaNova

Treatment Resistant Depression

02/28

12/30

Pollard, Ronnie

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

Matte, Raymond

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

Avalos, Moraima

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Allen, Rebecca H

uAspire, NCT06308653: Psilocybin for Major Depressive Disorder (MDD)

Recruiting

240

Usona Institute, Worldwide Clinical Trials

Depressive Disorder, Major

04/26

12/26

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

IMPACT-2, NCT06215261: An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD

Recruiting

Europe, US, RoW

Methylone

Transcend Therapeutics

Post Traumatic Stress Disorder

12/25

NCT05458037: RCT of Pain Perception With Fast and Slow Tenaculum Application

Recruiting

N/A

150

Speed of tenaculum application

Women and Infants Hospital of Rhode Island

Pain, Acute, Pain, Procedural

12/26

MeRT-TBI-005, NCT02990793: Clinical Trial to Evaluate the Safety and Efficacy of MeRT Treatment in Post-Traumatic Stress Disorder

Recruiting

N/A

152

Active MeRT Treatment, rTMS Active Stimulator, Sham MeRT Treatment, rTMS Sham Stimulator

Wave Neuroscience, Texas A&M University, GilpinPhillips BIOMED, LLC, Peachtree BioResearch Solutions

PostTraumatic Stress Disorder, Traumatic Brain Injury, Postconcussive Symptoms

08/25

10/25

MiMP, NCT05363371: Minds and Mentors Program- R33

Recruiting

N/A

240

Minds and Mentors, Twelve Step Intervention Group

University of Alabama, Tuscaloosa, University of Alabama at Birmingham, Tuscaloosa Veterans Affairs Medical Center, Pathway Healthcare, LLC

Opioid Use Disorder, Substance Use Disorders, Medication Assisted Treatment

08/24

OLO, NCT05819021: Open Label Optimization Study

Recruiting

N/A

1000

SAINT® Neuromodulation System (NMS), TMS

Magnus Medical

Major Depressive Disorder

10/26

04/27

Recruiting

N/A

6800

Vagus Nerve Stimulation (VNS), VNS

LivaNova

Treatment Resistant Depression

02/28

12/30

DiBuono, Mark

REGAiN-1B, NCT04873232: A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy

Completed

106

Engensis, Placebo

Helixmith Co., Ltd.

Diabetic Peripheral Neuropathy

09/23

07/24

NCT05397639 / 2021-003405-22: Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

Recruiting

375

Europe, US, RoW

Masupirdine 50 mg, SUVN-502, Masupirdine 100 mg, Placebo

Suven Life Sciences Limited, Suven Life Sciences Ltd

Agitation, Alzheimer's Type Dementia

12/25

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Terminated

1125

Canada, US, RoW

Simufilam, PTI-125, Placebo

Cassava Sciences, Inc., Premier Research Group plc

Alzheimer Disease

12/24

NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting

2996

Japan, US

Donanemab, LY3002813, Placebo

Eli Lilly and Company

Alzheimer Disease

11/27

NCT05439603: ANC-501 in the Treatment of Adults With Major Depressive Disorder

Completed

ANC-501

Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.

Major Depressive Disorder

08/23

10/23

NCT05081245: ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)

Recruiting

150

Canada, US, RoW

ML-004 (IR)/(ER) tablet, ML-004 Placebo

MapLight Therapeutics

Autism Spectrum Disorder

10/26

11/26

CYPRESS, NCT05895552: A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain

Terminated

209

RTA 901, BIIB143, Cemdomespib, RTA 901-Matching Placebo

Biogen

Diabetic Peripheral Neuropathic Pain

11/24

PROGRESS-AD, NCT06079190: Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

Active, not recruiting

367

Europe, Canada, US, RoW

GSK4527226, Placebo

GlaxoSmithKline, Alector Inc.

Alzheimer's Disease

11/26

NCT03788811: ERG Components in Schizophrenia and Bipolar Disorder Type I

Active, not recruiting

N/A

300

Canada, US, RoW

ERG assessment (RSPA)

diaMentis Inc.

Schizophrenia, Bipolar I Disorder

12/24

Robison, Reid

uAspire, NCT06308653: Psilocybin for Major Depressive Disorder (MDD)

Recruiting

240

Usona Institute, Worldwide Clinical Trials

Depressive Disorder, Major

04/26

12/26

NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

Active, not recruiting

255

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

06/25

04/26

EBS-101-TD-391, NCT06021522: A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

Recruiting

150

Europe, Canada, US, RoW

Ecopipam, Ecopipam Hydrochloride

Emalex Biosciences Inc.

Tourette Syndrome

12/26

03/27

D1AMOND, NCT05615220: Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults

Completed

216

Europe, Canada, US, RoW

Ecopipam Hydrochloride

Emalex Biosciences Inc.

Tourette Disorder

01/25

02/25

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

NCT05081245: ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)

Recruiting

150

Canada, US, RoW

ML-004 (IR)/(ER) tablet, ML-004 Placebo

MapLight Therapeutics

Autism Spectrum Disorder

10/26

11/26

BVR-100-102, NCT06037668: A Randomized, Controlled Study of Two At-Home Self-Guided Virtual Reality Interventions for Adults With Social Anxiety Disorder.

Completed

N/A

BVR-100, BES-100

Sumitomo Pharma America, Inc., BehaVR LLC

Social Anxiety Disorder (SAD)

12/23

01/24

Nery, Fabiano G

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

Duchemin, Anne-Marie

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

NCT06820723: A Mechanistic Study to Assess a Single Dose of CYB003 in Participants with Depression and Anxiety

Not yet recruiting

CYB003, Placebo

Ohio State University

Depression, Anxiety, Major Depressive Disorder

03/27

11/27

NCT05032105: The Impact of Focused Ultrasound Thalamotomy of the Anterior Nucleus for Focal-Onset Epilepsy on Anxiety

Recruiting

Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA)

Ohio State University

Anxiety, Medication-refractory Focal-onset Epilepsy

12/25

Recruiting

N/A

6800

Vagus Nerve Stimulation (VNS), VNS

LivaNova

Treatment Resistant Depression

02/28

12/30

House, Brindley

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

UNIKET, NCT05046184: Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets

Completed

165

Ketamine Hydrochloride, Midazolam injection

University of Texas Southwestern Medical Center

Major Depressive Disorder, Healthy Controls

04/25

Lindsay, Tenekia

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

Kwon, Sarah

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

ABT-CIP-10494, NCT06423430: Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

Recruiting

N/A

100

Sham-stimulation, Active-stimulation

Abbott Medical Devices

Treatment Resistant Depression

04/27

04/29

Recruiting

N/A

6800

Vagus Nerve Stimulation (VNS), VNS

LivaNova

Treatment Resistant Depression

02/28

12/30

Pollard, Ronnie

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

Matte, Raymond

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

Avalos, Moraima

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26



	Diseases Companies Products Productz Mechanisms of Action Sites